Achieve Life Sciences, Inc. a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisine for smoking cessation, today announced initiation of the Cytisine Clinical Development Program.
DBV Technologies announced that the first patient has been enrolled in EPITOPE ( EPIT in TO ddlers with PE anut Allergy), a global, Phase III clinical trial assessing the safety and efficacy of Viaskin Peanut for the treatment of peanut-allergic patients one to three years of age.
BioSight, Ltd, a pharmaceutical development company, focused on the development of targeted oncology therapeutics with reduced toxicity, announced completion of last patient treatment in its extended Phase I/II clinical study of BST-236 (Astarabine) in acute leukemia patients.
Kite Pharma, Inc , a leading cell therapy company announced that patients with relapsed/refractory indolent B-cell non-Hodgkin lymphoma (iNHL) are now being treated in its Phase 2 ZUMA-5 trial with its lead investigational candidate, axicabtagene ciloleucel (axi-cel).
Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT) (Intercept), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases,